MX2017011423A - Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer. - Google Patents

Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer.

Info

Publication number
MX2017011423A
MX2017011423A MX2017011423A MX2017011423A MX2017011423A MX 2017011423 A MX2017011423 A MX 2017011423A MX 2017011423 A MX2017011423 A MX 2017011423A MX 2017011423 A MX2017011423 A MX 2017011423A MX 2017011423 A MX2017011423 A MX 2017011423A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
inflammatory diseases
immune
morpholin
Prior art date
Application number
MX2017011423A
Other languages
English (en)
Inventor
Dymek Barbara
Zagozda Marcin
Wieczorek Maciej
DUBIEL Krzysztof
Stanczak Aleksandra
Zdzalik Daria
Gunerka Pawel
Sekular Mariola
Dziachan Maciej
Original Assignee
Celon Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Sa filed Critical Celon Pharma Sa
Publication of MX2017011423A publication Critical patent/MX2017011423A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula general (I), en la que Y representa -CH2- o >C=0; R1 se selecciona entre el grupo que consiste en A1, A2 y A3; R2 representa un resto dioxotiomorfolino B1, un resto piperazinilo B2, un resto azetidinilo B3 o un resto piperidinilo B4; R3 se selecciona entre el grupo que consiste en H, halógeno y alquilo C1 -C4; R4 se selecciona entre el grupo que consiste en alquilo C1 -C4, cicloalquilo C3-C4, alquilo C1-C4 sustituido con alcoxi C1-C4 y CHF2 y sus sales farmacéuticamente aceptables. Composiciones farmacéuticas que comprenden dichos compuestos y su uso en el tratamiento de enfermedades del sistema inmunológico, enfermedades inflamatorias y cáncer.
MX2017011423A 2015-04-02 2016-03-30 Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer. MX2017011423A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL411864A PL236355B1 (pl) 2015-04-02 2015-04-02 Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
PCT/IB2016/051792 WO2016157091A1 (en) 2015-04-02 2016-03-30 7-(morpholin-4-yl)pyrazole[1,5-a]pyrimidine derivatives which are useful for the treatment of immune or inflammatory diseases or cancer

Publications (1)

Publication Number Publication Date
MX2017011423A true MX2017011423A (es) 2018-05-17

Family

ID=55650626

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011423A MX2017011423A (es) 2015-04-02 2016-03-30 Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer.

Country Status (18)

Country Link
US (1) US10138247B2 (es)
EP (1) EP3277687B1 (es)
JP (1) JP6665201B2 (es)
KR (1) KR102559190B1 (es)
CN (1) CN107743489B (es)
AU (1) AU2016241568B2 (es)
BR (1) BR112017020131B1 (es)
CA (1) CA2978828A1 (es)
DK (1) DK3277687T3 (es)
EA (1) EA032826B1 (es)
ES (1) ES2765642T3 (es)
HR (1) HRP20192195T1 (es)
HU (1) HUE047822T2 (es)
MX (1) MX2017011423A (es)
PL (2) PL236355B1 (es)
PT (1) PT3277687T (es)
SI (1) SI3277687T1 (es)
WO (1) WO2016157091A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021347913A1 (en) * 2020-09-28 2023-05-18 1ST Biotherapeutics, Inc. Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191271B1 (pl) * 1996-02-07 2006-04-28 Neurocrine Biosciences Inc Pochodna pirazolopirymidyny i jej zastosowanie oraz kompozycja farmaceutyczna
WO2005062882A2 (en) 2003-12-23 2005-07-14 Activbiotics, Inc Rifamycin analogs and uses thereof
AU2006212457B2 (en) * 2005-02-11 2011-04-14 F. Hoffmann-La Roche Ag Pyrazolo-pyrimidine derivatives as mGLuR2 antagonists
MY146388A (en) * 2006-09-20 2012-08-15 Lilly Co Eli Thiazole pyrazolopyrimidines as crfi receptor antagonists
CN101835779B (zh) * 2007-10-26 2014-01-29 霍夫曼-拉罗奇有限公司 作为pi3激酶抑制剂的嘌呤衍生物
AU2009218515A1 (en) 2008-02-26 2009-09-03 Novartis Ag Heterocyclic compounds as inhibitors of CXCR2
KR20110042153A (ko) * 2008-05-30 2011-04-25 제넨테크, 인크. 퓨린 ｐｉ３ｋ 억제 화합물 및 사용 방법
US20110257170A1 (en) * 2008-10-03 2011-10-20 Merck Serono Sa 4-morpholino-pyrido[3,2-d]pyrimidines
WO2010074284A1 (ja) * 2008-12-26 2010-07-01 味の素株式会社 ピラゾロピリミジン化合物
SG175195A1 (en) * 2009-04-16 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
EP2451811A1 (en) 2009-05-27 2012-05-16 F. Hoffmann-La Roche AG Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
CA2761445A1 (en) * 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
GB0912745D0 (en) 2009-07-22 2009-08-26 Wolfson Microelectronics Plc Improvements relating to DC-DC converters
CN102762565A (zh) 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
CA2789475C (en) 2010-03-04 2018-05-29 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
US9096605B2 (en) * 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors

Also Published As

Publication number Publication date
EP3277687A1 (en) 2018-02-07
EA201792087A1 (ru) 2018-03-30
JP6665201B2 (ja) 2020-03-13
PL236355B1 (pl) 2021-01-11
US20180111939A1 (en) 2018-04-26
PL3277687T3 (pl) 2020-09-21
US10138247B2 (en) 2018-11-27
AU2016241568B2 (en) 2019-09-26
EP3277687B1 (en) 2019-10-30
JP2018510192A (ja) 2018-04-12
KR102559190B1 (ko) 2023-07-25
BR112017020131A2 (pt) 2018-05-29
WO2016157091A1 (en) 2016-10-06
DK3277687T3 (da) 2019-12-16
CN107743489A (zh) 2018-02-27
PT3277687T (pt) 2020-01-10
HUE047822T2 (hu) 2020-05-28
BR112017020131B1 (pt) 2023-02-28
PL411864A1 (pl) 2016-10-10
EA032826B1 (ru) 2019-07-31
SI3277687T1 (sl) 2020-02-28
HRP20192195T1 (hr) 2020-03-06
AU2016241568A1 (en) 2017-10-19
KR20170132275A (ko) 2017-12-01
ES2765642T3 (es) 2020-06-10
CA2978828A1 (en) 2016-10-06
CN107743489B (zh) 2021-05-04

Similar Documents

Publication Publication Date Title
NZ766835A (en) Pharmaceutical compounds
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
PH12018500437A1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
PH12018500958A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
EP3693369A3 (en) Bromodomain inhibitors
PH12017502171A1 (en) PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
PH12015501836A1 (en) 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2015014025A (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
NZ761680A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
MX2019010756A (es) Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2).
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
MX2017011423A (es) Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer.

Legal Events

Date Code Title Description
FG Grant or registration